Radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer

BMC Cancer

Yanlan Chai²  Tao Wang²  Juan Wang²  Yunyi Yang²  Ying Gao²  Jiyong Gao¹  Shangfeng Gao¹  Yueling Wang¹  Xi Zhou³  Zi Liu² 

[1] The Department of Gynecology of the 1st Affiliated Hospital, Xi’an Jiao Tong University, Xi’an 710061, China

[2] The Department of Radiotherapy Oncology of the 1st Affiliated Hospital, Xi’an Jiao Tong University, Xi’an 710061, China

[3] Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China

关键词: Adverse effects;    Radiotherapy;    Surgery;    Stage IIB;    Cervical carcinoma;   

Others  :  859094
DOI  :  10.1186/1471-2407-14-63

 received in 2013-11-01, accepted in 2014-01-28,  发布年份 2014

【 摘 要 】

Background

The goal of this study was to compare treatment outcomes for Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical carcinoma patients receiving radical surgery followed by adjuvant postoperative radiotherapy versus radical radiotherapy.

Methods

Medical records of FIGO stage IIB cervical cancer patients treated between July 2008 and December 2011 were retrospectively reviewed. A total of 148 patients underwent radical hysterectomy with pelvic lymph node dissection followed by adjuvant radiotherapy (surgery-based group). These patients were compared with 290 patients that received radical radiotherapy alone (RT-based group). Recurrence rates, progression-free survival (PFS), overall survival (OS), local control rates, and treatment-related complications were compared for these two groups.

Results

Similar rates of recurrence (16.89% vs. 12.41%, p = 0.200), PFS (log-rank, p = 0.211), OS (log-rank, p = 0.347), and local control rates (log-rank, p = 0.668) were observed for the surgery-based group and the RT-based group, respectively. Moreover, the incidence of acute grade 3–4 gastrointestinal reactions and late grade 3–4 lower limb lymphedema were significantly higher for the surgery-based group versus the RT-based group. Cox multivariate analyses found no significant difference in survival outcome between the two groups, and tumor diameter and histopathology were identified as significant prognostic factors for OS.

Conclusions

Radical radiotherapy was associated with fewer treatment-related complications and achieved comparable survival outcomes for patients with FIGO stage IIB cervical cancer compared to radical hysterectomy followed by postoperative radiotherapy.

【 授权许可】

   
2014 Chai et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S: Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation. Gynecol Oncol 2009, 114:69-148.
• [2]NCCN: Practice Guidelines in Oncology. 2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp webcite
• [3]Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the cervix uteri. Int J Gynaecol Obstet 2003, 83(Suppl 1):41-78.
• [4]Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C: Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet 1997, 350:535-540.
• [5]Undurraga M, Loubeyre P, Dubuisson JB, Schneider D, Petignat P: Early-stage cervical cancer: is surgery better than radiotherapy? Expert Rev Anticancer Ther 2010, 10:451-460.
• [6]Suprasert P, Srisomboon J, Kasamatsu T: Radical hysterectomy for stage IIB cervical cancer: a review. Int J Gynecol Cancer 2005, 15:995-1001.
• [7]Yamashita H, Nakagawa K, Tago M, Shiraishi K, Nakamura N, Ohtomo K, Oda K, Nakagawa S, Yasugi T, Taketani Y: Comparison between conventional surgery and radiotherapy for FIGO stage I–II cervical carcinoma: a retrospective Japanese study. Gynecol Oncol 2005, 97:834-839.
• [8]Ohara K, Sugahara S, Kagei K, Hata M, Igaki H, Tokuuye K, Akine Y: Retrospective comparison of clinical outcome between radiotherapy alone and surgery plus postoperative radiotherapy in the treatment of stages IB–IIB cervical squamous cell carcinoma. Radiat Med 2004, 22:42-48.
• [9]Mabuchi S, Okazawa M, Isohashi F, Matsuo K, Ohta Y, Suzuki O, Yoshioka Y, Enomoto T, Kamiura S, Kimura T: Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer. Gynecol Oncol 2011, 123(2):241-247.
• [10]Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ: A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006, 65(1):169-176.
• [11]Small W Jr, Mell LK, Anderson P, Creutzberg C, De Los SJ, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K, Mundt AJ: Consensus guidelines for delineation of clinical target volume for Intensity-Modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 2008, 71(2):428-434.
• [12]Oranusi CK, Nwofor A, Oranusi IO: Complication rates of open transvesical prostatectomy according to the Clavien–Dindo classification system. Niger J Clin Pract 2012, 15(1):34-37.
• [13]Park TK, Kwon JY, Kim SW, Kim SH, Kim SN, Kim GE: Patterns of treatment failure following radiotherapy with combination chemotherapy for patients with high-riskstage IIB cervical carcinoma. Int J Clin Oncol 2004, 9(2):120-124.
• [14]Einstein MH, Rash JK, Chappell RJ, Swietlik JM, Hollenberg JP, Connor JP: Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment. Gynecol Oncol 2012, 125(1):163-167.
• [15]Hsu WC, Chung NN, Chen YC, Ting LL, Wang PM, Hsieh PC, Chan SC: Comparison of surgery or radiotherapy on complications and quality of life in patients with the stage IB and IIA uterine cervical cancer. Gynecol Oncol 2009, 115(1):41-45.
• [16]Hasselle MD, Rose BS, Kochanski JD, Nath SK, Bafana R, Yashar CM, Hasan Y, Roeske JC, Mundt AJ, Mell LK: Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2011, 80:1436-1445.
• [17]Folkert MR, Shih KK, Abu-Rustum NR, Jewell E, Kollmeier MA, Makker V, Barakat RR, Alektiar KM: Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer. Gynecol Oncol 2013, 128(2):288-293.
• [18]Du XL, Tao J, Sheng XG, Lu CH, Yu H, Wang C, Song QQ, Li QS, Pan CX: Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy. Gynecol Oncol 2012, 125(1):151-157.
• [19]Chen SW, Liang JA, Yang SN, Liu RT, Lin FJ: The prediction of late rectal complications following the treatment of uterine cervical cancer by high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2000, 47(4):955-961.
• [20]Gondi V, Bentzen SM, Sklenar KL, Dunn EF, Petereit DG, Tannehill SP, Straub M, Bradley KA: Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis. Int J Radiat Oncol Biol Phys 2012, 84(4):973-982.
• [21]Gadducci A, Sartori E, Maggino T, Zola P, Cosio S, Zizioli V, Lapresa M, Piovano E, Landoni F: Pathological response on surgical samples is an independent prognostic variable for patients with Stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: An Italian multicenterretrospective study (CTF Study). Gynecol Oncol 2013., 3pii: S0090-8258(13)01203-1
• [22]Minig L, Colombo N, Zanagnolo V, Landoni F, Bocciolone L, Cárdenas-Rebollo JM, Iodice S, Maggioni A: Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB. Int J Gynecol Cancer 2013. [Epub ahead of print]
• [23]Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B: Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol 2007, 107:310-315.
• [24]Reig A, Membrive I, Foro P, Sanz X, Rodríguez N, Lozano J, Lacruz M, Quera J, Fernández-Velilla E, Algara M: Long-term results and prognostic factors of patients with cervical carcinoma treated with concurrent chemoradiotherapy. Clin Transl Oncol 2011, 13(7):504-508.
• [25]Xie XZ, Song K, Cui B, Jiang J, Zhang YZ, Wang B, Yang XS, Kong BH: Clinical and pathological factors related to the prognosis of Chinese patients with stage Ib to IIb cervical cancer. Asian Pac J Cancer Prev 2012, 13(11):5505-5510.
• [26]Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS, Hershman DL, Wright JD: Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 2012, 125(2):287-291.